



## Provepharm launches Blumyne surgical dye in UK

### **Blumyne™ provides healthcare professionals and hospitals with new, cost-efficient alternative indigo carmine dye for pelvic and abdominal surgery**

**Marseille, France, September 9, 2024** - Provepharm, a leading international pharmaceutical company specialising in medical dyes and antidotes, today announces the commercial launch of Blumyne™ on to the UK market. This indigo carmine dye is a licensed medicine indicated for the intra-operative detection of suspected ureteral injuries during abdominal and pelvic surgery.

[More than 50% of unintentional ureteric injuries may not be detected during surgery](#), which can cause serious complications for patients, such as sepsis and kidney failure. This risk can be mitigated during the primary procedure when an indigo carmine dye is injected to detect suspected ureteric injuries and reduce the risk of post-operative complications.

With only one indigo carmine dye currently licensed as a medicine for surgical use in the UK, the commercial launch of Blumyne™ (40mg/5ml) gives healthcare professionals a new, cost-efficient, therapeutic alternative. The product has applications across urological, gynaecological and colorectal surgeries. By selecting Provepharm, providers gain access to support from an independent company recognised as an expert in the surgical and endoscopic dye market. The opening of the UK affiliate in November 2023 ensures a direct line of customer assistance.

“I am thrilled to lead the national launch of Blumyne™; much welcomed on the UK market. Blumyne™ will introduce the potential for surgeons to reduce the risk of post-operative complications and save patients from needing further interventions due to ureteric injury, creating significant cost savings for the NHS. Provepharm’s years of expertise in the surgical dye market positions the company as a trusted supplier for UK healthcare providers,” said Tim Whelan, UK Country Manager at Provepharm and head of UK operations. “At Provepharm, we act to improve life and we aim to continue expanding the range of dyes available on the market to provide patients and healthcare professionals with a wider range of therapeutic solutions.”

Provepharm will continue to develop its range of dyes to cover surgical needs and reinforce knowledge on the benefits of dyes in clinical practice.

#### **About Provepharm – Act to improve life**

An independent, international specialty pharmaceutical company, Provepharm leverages the potential of well-known molecules to develop innovative solutions that satisfy hospital's unmet critical needs and help improve patients' lives. Provepharm develops, manufactures and markets a range of hospital products such as antidotes, and endoscopic and surgical dyes. Working closely with healthcare professionals, Provepharm is committed to developing specific services aimed at helping them enhance clinical practices. With a team of over 160 professionals and offices in France, the US and UK, the company markets its products in over 25 countries worldwide and devotes between 20% and 25% of its revenues to R&D.

The company strives every day to have a positive and significant social, societal and environmental impact in the performance of its activities: that's its *raison d'être*.



In November 2023, Provepharm joined the exclusive club of pioneering B Corp-certified pharmaceutical companies.

[www.provepharm.com](http://www.provepharm.com)

---

Media and analysts contact

**Andrew Lloyd & Associates**

Saffiyah Khaliq / Juliette Schmitt

[saffiyah@ala.associates](mailto:saffiyah@ala.associates) / [juliette@ala.associates](mailto:juliette@ala.associates)

UK: +44 1273 952 481

**Corporate Provepharm contact**

Mary ACARD DUYCK / Corporate Communication Department

[mary.acard-duyck@provepharm.com](mailto:mary.acard-duyck@provepharm.com)

+33 7 65 15 47 33

---